PMID- 30680005
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 17
IP  - 2
DP  - 2019 Feb
TI  - Potential role of poly (ADP-ribose) polymerase in delayed cerebral vasospasm 
      following subarachnoid hemorrhage in rats.
PG  - 1290-1299
LID - 10.3892/etm.2018.7073 [doi]
AB  - Poly (ADP-ribose) polymerase (PARP) serves a key role in several neurological 
      disorders, however, the specific role of PARP in delayed cerebral vasospasm 
      (DCVS) following subarachnoid hemorrhage (SAH) remains unclear. The present study 
      was conducted to clarify the possible mechanism of PARP in DCVS with the 
      treatment of 3-aminobenzamide (3-AB), a PARP inhibitor. In the preliminary 
      experiment, an internal carotid artery puncture SAH model, a cisterna magna 
      double injection SAH model and prechiasmatic cistern single injection SAH model 
      were compared with respect to mortality and neurobehavioral test results. The 
      prechiasmatic cistern single injection SAH model was chosen to induce DCVS in the 
      formal experiment. In the formal experiment, a total of 96 Sprague Dawley rats 
      were randomly allocated into the sham group, the SAH group and the SAH+3-AB group 
      and then each group was further subdivided into days 3, 5, 7 and 14 post-SAH 
      subgroups (n=8 for each subgroup). The prechiasmatic cistern single injection SAH 
      model was established to induce DCVS. Neurobehavioral testing and HE staining 
      were conducted to evaluate the degree of cerebral vasospasm. PARP activity was 
      assessed by ELISA and immunohistochemistry. An electrophoretic mobility shift 
      assay was used to detect nuclear factor (NF)-kappaB DNA-binding activity. The 
      expression of monocyte chemotactic protein 1 (MCP-1) and C-reactive protein (CRP) 
      were measured by western blotting. Cerebral vasospasm occurred following SAH and 
      became most severe on around day 7 post-SAH. NF-kappaB activity, PARP activity, the 
      expression of MCP-1 and CRP exhibited a similar time course to cerebral 
      vasospasm. Treatment with 3-AB alleviated the degree of cerebral vasospasm. NF-kappaB 
      activity, PARP activity and the expression of MCP-1 and CRP were also suppressed 
      by 3-AB treatment. In conclusion, PARP may serve an important role in regulating 
      the inflammatory response and ultimately contribute to DCVS. Therefore 3-AB may 
      be a potential therapeutic agent for DCVS.
FAU - Fan, Yameng
AU  - Fan Y
AD  - Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, 
      Shaanxi 710061, P.R. China.
FAU - Yan, Ge
AU  - Yan G
AD  - Department of Medical Image, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Liu, Furong
AU  - Liu F
AD  - Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, 
      Shaanxi 710061, P.R. China.
FAU - Rong, Jie
AU  - Rong J
AD  - Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, 
      Shaanxi 710061, P.R. China.
FAU - Ma, Wenxia
AU  - Ma W
AD  - Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, 
      Shaanxi 710061, P.R. China.
FAU - Yang, Danrong
AU  - Yang D
AD  - Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, 
      Shaanxi 710061, P.R. China.
FAU - Yu, Yan
AU  - Yu Y
AD  - Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, 
      Shaanxi 710061, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181207
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6327579
OTO - NOTNLM
OT  - 3-AB
OT  - delayed cerebral vasospasm
OT  - inflammatory response
OT  - nuclear factor-kappaB
OT  - poly ADP-ribose polymerase
OT  - subarachnoid hemorrhage
EDAT- 2019/01/27 06:00
MHDA- 2019/01/27 06:01
PMCR- 2018/12/07
CRDT- 2019/01/26 06:00
PHST- 2018/04/06 00:00 [received]
PHST- 2018/11/14 00:00 [accepted]
PHST- 2019/01/26 06:00 [entrez]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2019/01/27 06:01 [medline]
PHST- 2018/12/07 00:00 [pmc-release]
AID - ETM-0-0-7073 [pii]
AID - 10.3892/etm.2018.7073 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Feb;17(2):1290-1299. doi: 10.3892/etm.2018.7073. Epub 2018 Dec 
      7.